US EditionElraglusib Significantly Lowers Risk of Death in PDAC Patients: Trial
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Elraglusib significantly lowers risk of death in PDAC patients: Trial
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC). That’s according to top-line findings from Part 3B of the Phase 1/2 Actuate-1801 trial (NCT03678883) that were recently presented at the American Society of Clinical Oncology (ASCO) annual meeting. …
ONCOLOGICAL JOURNAL Danish research has significantly increased survival for patients with pancreatic cancer In a small Danish study, oncologists at Herlev and Gentofte Hospital have achieved a remarkably high survival rate among patients with locally advanced or metastatic pancreatic cancer. The results give us hope that we are on the trail of an effective new treatment for these hard-hit patients, says the study's lead author, senior physician…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
